for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Abbott Laboratories

ABT.N

Latest Trade

108.36USD

Change

0.32(+0.30%)

Volume

1,107,435

Today's Range

108.16

 - 

109.89

52 Week Range

61.62

 - 

114.19

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
108.04
Open
108.26
Volume
1,107,435
3M AVG Volume
110.17
Today's High
109.89
Today's Low
108.16
52 Week High
114.19
52 Week Low
61.62
Shares Out (MIL)
1,770.53
Market Cap (MIL)
191,288.10
Forward P/E
--
Dividend (Yield %)
1.33

Next Event

Q3 2020 Abbott Laboratories Earnings Release

Latest Developments

更多

Abbott Receives FDA Emergency Use Authorization For COVID-19 IgM Antibody Blood Test

Abbott Secures CE Mark For Next-Generation Freestyle Libre 3 System

Abbott Laboratories- Freestyle Libre 2 Now Available To Medicare Patients

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.

Industry

Medical Equipment & Supplies

Contact Info

100 Abbott Park Rd

ABBOTT PARK, IL

60064-3500

United States

+1.224.6676100

https://www.abbott.com

Executive Leadership

Miles D. White

Executive Chairman of the Board

Robert B. Ford

President, Chief Executive Officer, Chief Operating Officer, Director

Robert E. Funck

Chief Financial Officer, Executive Vice President - Finance

Hubert L. Allen

Executive Vice President, General Counsel, Secretary

Mary K. Moreland

Executive Vice President of Human Resources

Key Stats

1.90 mean rating - 21 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

27.4K

2018

30.6K

2019

31.9K

2020(E)

33.2K
EPS (USD)

2017

2.500

2018

2.880

2019

3.240

2020(E)

3.325
Price To Earnings (TTM)
62.50
Price To Sales (TTM)
6.08
Price To Book (MRQ)
6.26
Price To Cash Flow (TTM)
30.63
Total Debt To Equity (MRQ)
64.36
LT Debt To Equity (MRQ)
59.47
Return on Investment (TTM)
5.28
Return on Equity (TTM)
4.49

Latest News

Latest News

Abbott wins U.S. emergency use authorization for new COVID-19 antibody test

Abbott Laboratories said on Monday the U.S. Food and Drug Administration has issued an emergency use authorization for its lab-based COVID-19 antibody blood test.

UPDATE 2-Abbott says new data shows rapid COVID-19 test used at White House is highly accurate

Abbott Laboratories on Wednesday released early data from a study on the accuracy of its ID NOW COVID-19 test, which is used in the White House, that could help alleviate concerns the diagnostic frequently fails to detect the virus.

Abbott says ID NOW COVID-19 rapid test shows high sensitivity in study

Abbott Laboratories said on Wednesday its ID NOW COVID-19 rapid test showed 96.2% sensitivity and 99.5% specificity compared to lab-based molecular PCR tests, according to interim data from a study.

REFILE-UPDATE 1-INSIGHT-Relying on testing to ward off COVID put Trump White House at risk

Early in the coronavirus pandemic, U.S. President Donald Trump put his faith in a toaster-sized machine that could spit out test results in a matter of minutes.

INSIGHT-Relying on testing to ward off COVID put Trump White House at risk

Early in the coronavirus pandemic, U.S. President Donald Trump put his faith in a toaster-sized machine that could spit out test results in a matter of minutes.

Abbott wins EU approval for smallest version of glucose monitoring device

Abbott Laboratories' said on Monday it had received clearance to market the smallest version of its fastest-growing low-cost diabetes monitoring product in the European Union.

UPDATE 2-U.S. to send millions of rapid COVID-19 tests to states to support school reopening, other tasks

The U.S. government will send an "overwhelming majority" of the rapid COVID-19 tests it purchased from Abbott Laboratories last week to governors of states and territories to support school reopenings and other critical tasks, an administration official said at a press briefing...

UPDATE 1-U.S. to send millions of rapid COVID-19 tests to states to support school reopening, other tasks

The U.S. government will send an "overwhelming majority" of the rapid COVID-19 tests it purchased from Abbott Laboratories last week to governors of states and territories to support school reopenings and other critical tasks, an administration official said at a press briefing...

UPDATE 1-Trump administration to purchase 150 mln Abbott COVID-19 tests for $750 mln

The Trump administration will purchase 150 million rapid coronavirus tests from Abbott Laboratories for about $750 million, a White House spokeswoman said on Thursday.

Trump administration to purchase 150 million Abbott COVID-19 tests for $750 mln

The Trump administration will purchase 150 million rapid coronavirus tests from Abbott Laboratories for about $750 million, a White House spokeswoman said on Thursday.

REFILE-UPDATE 1-Abbott wins U.S. authorization for $5 rapid COVID-19 antigen test

Abbott Laboratories said on Wednesday it won U.S. marketing authorization for a COVID-19 portable antigen test that can deliver results within 15 minutes and will sell for $5.

Abbott wins U.S. approval for rapid COVID-19 test

Abbott Laboratories said on Wednesday it won U.S. marketing approval for a COVID-19 portable test that can deliver results within 15 minutes.

UPDATE 3-Abbott sees no hit to demand for COVID-19 tests from vaccine

Abbott Laboratories said on Thursday demand for its coronavirus tests will likely remain high even after a safe and effective vaccine is available as the medical device maker forecast full-year profit above analysts' estimates.

REFILE-Abbott CEO expects high demand for antibody tests even after approved COVID-19 vaccine

Abbott Laboratories expects to see higher demand for serology and antibody testing for the new coronavirus, even after a vaccine becomes available, Chief Executive Officer Robert Ford said on a post-earnings conference call on Thursday.

Abbott quarterly profit plunges as COVID-19 batters medical device unit

Abbott Laboratories on Thursday reported a 46.6% fall in second-quarter profit as the COVID-19 pandemic continued to batter its medical device unit.

UPDATE 2-U.S. FDA clears new version of Abbott's low-cost glucose monitor

The U.S. Food and Drug Administration on Monday cleared a new version of Abbott Laboratories' continuous glucose monitoring device, helping the company build upon the success of its fastest-growing diabetes product.

U.S. FDA clears version 2.0 of Abbott's low-cost glucose monitor

The U.S. Food and Drug Administration on Monday cleared a new version of Abbott Laboratories' continuous glucose monitoring device.

Abbott says new data on rapid coronavirus test used in White House shows high accuracy

Abbott Laboratories on Thursday said an analysis of data from an ongoing study of its ID NOW rapid test, which is used in the White House and elsewhere to spot COVID-19, shows it is highly accurate when compared with industry-standard tests.

U.S. FDA authorizes use of Abbott's COVID-19 antibody test on second system

The U.S. Food and Drug Administration on Monday authorized the emergency use of Abbott Laboratories' coronavirus test for detecting antibodies using another of its diagnostic platforms, which will allow the company to ship nearly 30 million tests this month.

Study suggests Abbott COVID-19 antibody test highly likely to give correct results

Abbott Laboratories' antibody test for the new coronavirus is highly likely to correctly determine whether people have ever been infected with the fast-spreading virus, the company said, citing a U.S. study.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up